Another limitation of our study is the lack of testing for activating EGFR-mutations although it has an important effect on patients’ survival28, due to the fact that this was not part of the clinical routine in 2000–2005, when our patients were diagnosed with lung cancer. The gene discussed is EGFR; the disease is lung carcinoma.